List of Excipients in Branded Drug FLURANDRENOLIDE CREAM

« Back to Dashboard

Generic Drugs Containing FLURANDRENOLIDE CREAM

Company	Ingredient	NDC	Excipient
Cintex Services LLC	flurandrenolide	24470-919	CETYL ALCOHOL
Cintex Services LLC	flurandrenolide	24470-919	CITRIC ACID MONOHYDRATE
Cintex Services LLC	flurandrenolide	24470-919	MINERAL OIL
Cintex Services LLC	flurandrenolide	24470-919	POLYOXYL 40 STEARATE

What are the Most Frequently-Used Excipients in FLURANDRENOLIDE CREAM?

# Of NDCs	Excipient
1	CETYL ALCOHOL
1	CITRIC ACID MONOHYDRATE
1	MINERAL OIL
1	POLYOXYL 40 STEARATE

Flurandrenolide Cream Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 15, 2026

Flurandrenolide cream is a legacy topical corticosteroid opportunity with limited compound-level exclusivity and meaningful formulation differentiation potential. The strongest commercial strategies are a reliable generic 0.05% cream, a lower-irritancy formulation, improved packaging, and targeted dermatology distribution. Regulatory success will depend on pharmaceutical equivalence, comparative product performance, preservative control, and consistent topical delivery rather than on new active-ingredient patents.

What is flurandrenolide cream and where does it compete?

Flurandrenolide is a synthetic topical corticosteroid used for inflammatory and pruritic corticosteroid-responsive dermatoses. The marketed cream strength is generally 0.05% w/w. The product is prescription-only in the United States and is positioned against other topical corticosteroids, including triamcinolone acetonide, hydrocortisone, betamethasone valerate, fluocinolone acetonide, and fluocinonide.[1,2]

The commercial product category is mature. Physicians typically select among topical steroids based on potency, site of application, vehicle acceptability, prior patient response, price, and formulary status. Flurandrenolide cream therefore competes less on molecular novelty and more on:

• Consistent potency and dose delivery
• Skin feel and cosmetic acceptability
• Low irritation potential
• Generic substitution and reimbursement
• Availability in preferred tube sizes
• Packaging that limits contamination and waste
• Supply reliability

Flurandrenolide should be positioned as a differentiated topical steroid cream rather than as a novel dermatology active.

What excipients are most important in flurandrenolide cream?

The excipient system should provide chemical stability, uniform drug distribution, suitable release from the semisolid base, acceptable skin feel, and microbiological robustness. A conventional oil-in-water or water-containing emulsion is the most commercially practical platform for a cream product.

Recommended excipient architecture

Formulation function	Candidate excipient classes	Commercial objective
Continuous phase	Purified water, mineral oil, or other approved emollient phase	Controls texture and application
Emulsification	Glyceryl stearate, polysorbates, nonionic emulsifiers, fatty alcohols	Maintains physical stability
Consistency	Cetyl alcohol, stearyl alcohol, cetostearyl alcohol, waxes	Controls viscosity and spreadability
Humectancy	Propylene glycol, glycerin, sorbitol	Limits drying and improves feel
Emolliency	Mineral oil, isopropyl myristate, esters, hydrocarbons	Improves skin conditioning
Preservation	Sorbic acid, parabens, phenoxyethanol, benzoate systems, or other suitable preservatives	Controls microbial growth
Chelation and buffering	Citrate, phosphate, EDTA systems where justified	Supports stability and preservative performance
Rheology control	Carbomers, cellulose derivatives, gums, or structured fatty alcohol systems	Controls yield value and phase separation
pH adjustment	Citric acid, sodium citrate, phosphates, or approved bases	Supports stability and skin tolerability

The selected excipients must be appropriate for topical use and supported by toxicological, compendial, and regulatory data. FDA’s Inactive Ingredient Database is a central reference for prior use levels and route-specific precedent.[3]

Why fatty alcohols matter

Cetyl alcohol, stearyl alcohol, and cetostearyl alcohol can provide structure, emulsion stability, and a rich skin feel. They are often more useful than high levels of polymeric thickeners when the target is a conventional dermatology cream.

The main risks are wax crystallization, batch-to-batch viscosity drift, and a heavy or greasy after-feel. The formulation should control the cooling profile and mixing energy because the internal structure of the cream can affect drug release and patient acceptance.

Why propylene glycol requires careful control

Propylene glycol can function as a humectant, solvent, and penetration-supporting excipient. It may improve drug solubilization and release, but higher levels can increase stinging or irritation in compromised skin. The optimal concentration should be selected through comparative release, irritation, and sensory testing rather than by maximizing apparent solubility.

A lower-irritancy formulation could use a mixed humectant system or reduce the solvent burden while maintaining drug uniformity. That approach may offer a commercial advantage for patients with eczema, fissured skin, or frequent application needs.

Preservative strategy

A water-containing cream generally requires a validated antimicrobial preservation system unless the product is manufactured and packaged under a design that eliminates the need for a preservative. The preservative must remain effective in the final emulsion, including after partitioning into the oil phase or adsorption onto packaging.

The product should undergo antimicrobial effectiveness testing under USP <51> or the applicable jurisdictional standard, along with microbial limits testing under USP <61> and related methods.[4] Preservative optimization should consider:

• pH-dependent activity
• Partitioning between oil and water phases
• Compatibility with the tube or pump
• Patient sensitivity and contact dermatitis risk
• Manufacturing bioburden
• In-use contamination

A preservative-free multidose cream may be commercially attractive, but it creates a higher packaging and microbiology burden. A single-use or unit-dose format can reduce contamination risk but usually carries higher packaging and distribution costs.

What formulation characteristics should support an abbreviated approval?

For a generic flurandrenolide cream, the key objective is to demonstrate pharmaceutical equivalence and comparable product performance to the reference product. FDA’s guidance for topical dermatological products emphasizes a product-specific assessment that can include qualitative and quantitative composition, physicochemical properties, performance testing, and, where required, comparative clinical or in vivo evidence.[5]

The formulation should target:

1. The same active concentration, 0.05% w/w.
2. Comparable dosage form and route of administration.
3. Comparable inactive-ingredient composition where practical.
4. Similar appearance, viscosity, pH, globule size, and rheology.
5. Comparable drug release and permeation behavior.
6. Adequate content uniformity across the package.
7. Comparable microbial quality and preservative effectiveness.
8. Stability throughout the proposed shelf life.

For topical creams, Q1/Q2 sameness can reduce regulatory risk, but it can also limit the ability to create a clearly differentiated product. A Q1/Q2 formulation may be preferable for a first generic launch. A second product can pursue lower-irritancy or improved sensory attributes after the core ANDA is established.

What formulation patents could protect flurandrenolide cream?

The active ingredient and basic cream concept are unlikely to provide a durable modern exclusivity position because flurandrenolide has been marketed for decades. Any original compound, basic use, or legacy formulation patents should be presumed expired unless a current patent search establishes otherwise.

Potentially protectable subject matter includes:

• A narrowly defined excipient ratio
• A specific emulsion architecture
• A preservative-free multidose system
• A low-irritancy vehicle
• A controlled-release or enhanced-retention cream
• A metered-dose topical delivery system
• A package-and-formulation combination
• A manufacturing process that produces a defined particle or droplet distribution
• A method of reducing transfer, staining, or residue
• A formulation designed for a specific dermatologic site

The strongest patent claims would need measurable technical limitations and a credible performance benefit. Broad claims covering “flurandrenolide in a cream” would face significant validity risk based on the long history of topical corticosteroid creams.

Patentability priorities

A new formulation program should generate comparative data against the reference product and leading generic creams. Useful claim-supporting endpoints include:

• Lower evaporative water loss after application
• Reduced stinging in a validated irritation model
• Improved drug release under standardized conditions
• Lower residue or transfer to clothing
• Better stability under accelerated conditions
• Reduced preservative concentration with equivalent microbial protection
• Improved dose uniformity from the final package
• Lower application force or improved dispensing accuracy

The technical effect must be linked to the claimed excipient combination. Merely substituting one conventional emollient for another is unlikely to create a strong patent position without unexpected performance.

When does flurandrenolide cream lose exclusivity?

Flurandrenolide cream is an old, non-biologic topical drug. Its principal market barrier is not expected to be active-ingredient exclusivity. The relevant commercial exclusivity question is whether an approved reference product has remaining regulatory exclusivity or whether an applicant has obtained a limited period of generic exclusivity through an ANDA challenge.

A launch assessment should examine:

Exclusivity issue	Relevance to flurandrenolide cream
New chemical entity exclusivity	Not commercially relevant for this legacy active
Orphan-drug exclusivity	Not expected for ordinary flurandrenolide cream
Pediatric exclusivity	Must be checked against any specific reference-product record
Three-year exclusivity	Could apply only to qualifying new clinical investigations
ANDA 180-day exclusivity	Could arise from a first Paragraph IV applicant
Patent exclusivity	Depends on current listed patents and expiration dates
OTC switch exclusivity	Not relevant unless FDA approves a specific switch

The Orange Book should be reviewed for the precise reference product, listed patents, use codes, and exclusivity codes before a Paragraph IV strategy is selected.[6]

What is the Orange Book and Paragraph IV position?

A generic applicant may submit an ANDA with Paragraph III or Paragraph IV certifications, depending on the patents listed for the reference product. Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.[7]

For an old topical corticosteroid, the likely opportunity is a patent-light ANDA rather than a patent litigation strategy. A Paragraph IV filing would still require:

• Confirmation of listed patents in the Orange Book
• Review of patent expiration and pediatric dates
• Analysis of use codes
• Noninfringement and invalidity positions
• Assessment of a possible 30-month stay
• Evaluation of first-filer economics
• Review of settlement restrictions

No commercial plan should assume 180-day exclusivity without confirming that the applicable patent certifications and forfeiture provisions are satisfied.

What litigation and settlement risks affect the product?

The most likely disputes involve formulation patents, process patents, labeling, and regulatory exclusivity rather than the flurandrenolide molecule itself. A company pursuing a differentiated cream should conduct freedom-to-operate work in the United States, Europe, Canada, and other target markets because formulation patents can remain enforceable after original compound patents expire.

Relevant litigation questions include:

• Whether a proposed excipient ratio falls within a live formulation claim
• Whether a delivery package is covered by a device or combination patent
• Whether a proposed label induces infringement of a method-of-use claim
• Whether a manufacturing process uses a patented homogenization or particle-size method
• Whether a settlement delays launch beyond the earliest non-infringing date

Settlement agreements can also affect launch timing and supply arrangements. Any settlement involving a first filer should be reviewed for payment, licensing, authorized-generic, and launch-date provisions.

What FDA regulatory status applies to flurandrenolide cream?

Flurandrenolide cream is regulated as a prescription topical corticosteroid. The label includes standard corticosteroid warnings concerning systemic absorption, hypothalamic-pituitary-adrenal axis suppression, pediatric use, treatment duration, occlusion, and application to sensitive body sites.[1]

Regulatory development should address:

• Active-ingredient identity and assay
• Impurity and degradation-product control
• Homogeneity and content uniformity
• In vitro release testing
• Rheology and viscosity
• Particle or droplet-size distribution
• Microbial quality
• Preservative effectiveness
• Container-closure compatibility
• In-use stability
• Photostability and temperature cycling
• Dermal irritation and sensitization risk

The product should not be positioned for unapproved indications or body sites. Combination products with antifungals, antibacterials, retinoids, or keratolytics would require separate regulatory and clinical analysis.

Which commercial opportunities are most attractive?

1. Low-cost generic cream

The lowest-risk strategy is a Q1/Q2-matched cream in standard tube sizes. It can compete through manufacturing efficiency, reliable supply, and wholesaler coverage. This segment is likely price-sensitive and may experience rapid erosion after multiple ANDA approvals.

2. Lower-irritancy cream

A formulation that reduces stinging, residue, or excessive greasiness could command better pharmacy and dermatology acceptance. Evidence would need to show a meaningful product attribute rather than only a different excipient list.

3. Improved packaging

A metered pump, airless package, or controlled-dispense tube could reduce contamination and improve dose consistency. Packaging must not create a new human-factors problem or materially increase cost.

4. Specialty dermatology distribution

A company could target dermatology practices, specialty pharmacies, and payer formularies with dependable supply and patient-support programs. This is a channel strategy rather than a patent moat.

5. International licensing

Licensing opportunities may exist in markets where topical corticosteroid access is fragmented or where local manufacturing is required. The commercial case depends on registration status, local reference products, import controls, and reimbursement. A license should include rights to the formulation, manufacturing process, packaging, trademarks, and regulatory dossier.

6. Contract manufacturing

Flurandrenolide cream can fit a broader dermatology contract-manufacturing portfolio. Manufacturers with validated semisolid facilities can use the product to fill capacity between higher-value topical programs.

How does flurandrenolide cream compare with competing topical steroids?

Product	Typical commercial position	Competitive advantage
Hydrocortisone	Lower-potency, broad retail and prescription use	Familiarity and low cost
Triamcinolone acetonide	High-volume mid-potency generic	Strong formulary presence
Betamethasone valerate	Potency and formulation variety	Established physician use
Fluocinolone acetonide	Multiple topical vehicles	Broad dermatology coverage
Fluocinonide	Higher-potency option	Strong anti-inflammatory effect
Flurandrenolide	Legacy, narrower niche	Potential for differentiated vehicle and reliable supply

Flurandrenolide is unlikely to win a volume contest against triamcinolone acetonide. Its stronger opportunity is a focused product with superior tolerability, dispensing, or availability.

What revenue exposure should investors model?

Standalone flurandrenolide revenue is difficult to isolate because sales may be reported within broader dermatology, topical corticosteroid, or generic portfolios. A commercial model should therefore use bottom-up assumptions:

• Addressable prescriptions
• Average grams per prescription
• Net price per tube
• Generic price erosion
• Number of competing suppliers
• Formulary access
• Dermatology versus primary-care mix
• Manufacturing cost per kilogram and per tube
• Retail, specialty, and hospital channel mix

The core generic should be modeled as a low-margin, volume-dependent product. A differentiated formulation can support higher net pricing, but only if the clinical or user benefit is documented and reimbursement does not treat it as interchangeable with the commodity generic.

Key Takeaways

• Flurandrenolide cream is a mature topical corticosteroid opportunity centered on formulation execution.
• The standard commercial strength is 0.05% w/w.
• A conventional emulsion with controlled fatty alcohols, humectants, emollients, preservatives, and rheology modifiers is the practical development platform.
• Propylene glycol, preservative selection, pH, and emulsion structure require optimization for irritation, stability, and drug release.
• A Q1/Q2-oriented generic is the lowest-risk regulatory route.
• The likely patent opportunity lies in specific excipient systems, delivery packages, manufacturing processes, and measurable performance benefits.
• Compound-level exclusivity should not be treated as the principal barrier.
• The most attractive differentiated opportunities are lower-irritancy vehicles, improved dispensing systems, and dependable specialty distribution.
• Revenue modeling should account for rapid generic price erosion and the limited standalone visibility of legacy topical products.
• Orange Book, patent, litigation, and settlement records must be reviewed for the exact reference product before filing or licensing decisions.

FAQs About Flurandrenolide Cream

Is flurandrenolide cream a high-potency steroid?

Flurandrenolide 0.05% cream is generally positioned as a moderate-potency topical corticosteroid. Potency can vary with vehicle, application site, occlusion, and formulation performance.

Can a preservative-free flurandrenolide cream be commercialized?

Yes, but the product requires a packaging and microbiological strategy that controls contamination throughout use. Airless pumps, unit-dose systems, or other protective packages may be necessary.

Can flurandrenolide cream be sold over the counter?

A prescription-to-OTC switch would require a separate FDA review, consumer-labeling evidence, self-selection data, and a determination that the condition can be treated safely without professional diagnosis.

Does a new flurandrenolide excipient combination automatically receive patent protection?

No. Patentability depends on novelty, non-obviousness, adequate disclosure, and defensible claim scope. A conventional substitution of known cream ingredients may not support a strong patent.

What is the best first development program for a generic manufacturer?

The most practical program is a compositionally close 0.05% cream with robust control of assay, uniformity, rheology, in vitro release, preservative effectiveness, microbial quality, and container-closure performance.

References

1. U.S. Food and Drug Administration. (n.d.). Flurandrenolide topical cream prescribing information. Drugs@FDA and product labeling database.

2. National Library of Medicine. (n.d.). DailyMed: Flurandrenolide cream. DailyMed drug labeling database.

3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA Center for Drug Evaluation and Research.

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: General chapters <51>, <61>, and <62>.

5. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatological drug product development and abbreviated new drug application submissions. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

7. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Patent certification and approval provisions. Center for Drug Evaluation and Research.